GlassScriptPhysician profile
M Ashraf Meelu
NPI 1255489027
$19,231.76
in general payments reported to CMS, 2019-2025
77 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $2,695 · 2021: $3,850 · 2022: $3,086 · 2023: $2,998 · 2024: $2,335 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,715 · Long Term Medical Supply Or Device Loan: $1,164 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,714.57 |
| Long Term Medical Supply Or Device Loan | $1,163.66 |
| Education | $268.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,618.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,815.11 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,250.41 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Pfizer INC. | $1,078.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $763.78 | 2019-2025 | Opdivo, Eliquis, Augtyro |
| Celgene Corporation | $710.30 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $580.30 | 2019-2024 | Padcev |
| Astellas Pharma US INC | $576.58 | 2020-2025 | Padcev, Cresemba, Xtandi |
| Amgen INC. | $562.43 | 2019-2024 | Kyprolis, Lumakras, Evenity |
| Incyte Corporation | $487.41 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $486.77 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Lilly USA, LLC | $408.63 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Rigel Pharmaceuticals, INC. | $384.32 | 2019-2023 | Rezlidhia, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $360.78 | 2019-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $329.04 | 2021-2025 | Injectafer, Enhertu |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Meelu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.